Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.

ABSTRACT:

Introduction

The use of tumor-selectively replicating viruses is a rapidly expanding field that is showing considerable promise for cancer treatment. Retroviral replicating vectors (RRV) are unique among the various replication-competent viruses currently being investigated for potential clinical utility, because they permanently integrate into the cancer cell genome and are capable of long-term persistence within tumors. RRV can mediate efficient tumor-specific delivery of prodrug activator genes, and subsequent prodrug treatment leads to synchronized cell killing of infected cancer cells, as well as activation of antitumor immune responses.

Areas covered

Here we review preclinical studies supporting bench-to-bedside translation of Toca 511, an optimized RRV for prodrug act

SUBMITTER: Collins SA 

PROVIDER: S-EPMC8429069 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature